Human papillomavirus in high-grade cervical lesions: Austrian data of a European multicentre study

被引:6
|
作者
Roessler, Lucia [1 ]
Reich, Olaf [2 ]
Horvat, Reinhard [3 ]
de Souza, Sabrina Collas [4 ]
Holl, Katsyarina [5 ]
Joura, Elmar A. [1 ]
机构
[1] Med Univ Vienna, Dept Gynaecol & Obstet, Ctr Comprehens Canc, A-1090 Vienna, Austria
[2] Med Univ Vienna, Dept Gynaecol & Obstet, A-1090 Vienna, Austria
[3] Med Univ Vienna, Inst Clin Pathol, A-1090 Vienna, Austria
[4] GlaxoSmithKline Vaccines, Clin 4, Paris, France
[5] GlaxoSmithKline Vaccines, Wavre, Belgium
关键词
Epidemiology; Human papillomavirus; HPV high-risk types; Cervical dysplasia; Cervical cancer; HPV-16/18 AS04-ADJUVANTED VACCINE; CROSS-PROTECTIVE EFFICACY; OF-STUDY ANALYSIS; INTRAEPITHELIAL NEOPLASIA; PERINATAL-MORTALITY; PARTICLE VACCINE; HPV TYPES; WOMEN; DISEASE; CANCER;
D O I
10.1007/s00508-013-0403-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purpose is to present the Austrian data of an observational, cross-sectional, multicentre study conducted in 13 European countries. This study was undertaken to assess human papillomavirus (HPV) type distribution in high-grade cervical lesions. Two hundred and ninety cases of high-grade cervical intraepithelial neoplasia (CIN2, CIN3) or adenocarcinoma in situ of the cervix from 2004 to 2007 were analysed by histopathological review and polymerase chain reaction for HPV. Two hundred and nine cases were "histologically eligible" and of those 206 were HPV+. Median age was 34 years (19-76 years). CIN3 was the most frequent diagnosis (64.6 %), followed by CIN2/3 (19.4 %) and CIN2 (13.6 %). Adenocarcinoma in situ was only detected together with a squamous lesion in 2.4 % cases. Majority of women (75.2 %) were infected with a single HPV type, 98.1 % of them with high-risk HPV types: HPV 16 (56.1 %), HPV 33 (12.3 %), HPV 31 (11.0 %), HPV 18 (3.9 %), HPV 35 (3.9 %), HPV 51 (3.2 %) and HPV 52 (2.6 %), HPV 58 (1.9 %) and HPV 45 (0.6 %). The low-risk HPV 6 was found in 1.3 % cases. Forty-six lesions (22.3 %) contained multiple infections, 71.1 % of those were HPV 16 or 18 and 91.1 % were HPV 16, 18, 31, 33 or 45 positive. These Austrian data clearly demonstrate that HPV 16 is the predominant type in high-grade CIN, the immediate precursor lesions of cervical cancer. More than 60 % of the lesions were associated with HPV 16 and 18 and more than 85 % with HPV 16, 18, 31, 33 or 45. The prevalence of adenocarcinoma in situ is underestimated, since its detection is difficult with the current cytology screening.
引用
收藏
页码:591 / 599
页数:9
相关论文
共 50 条
  • [31] Do Infection Patterns of Human Papillomavirus Affect the Cytologic Detection of High-Grade Cervical Lesions on Papanicolaou Tests?
    Samimi, Siavash Azadmanesh
    Mody, Roxanne R.
    Goodman, Steven
    Luna, Eric
    Armylagos, Donna
    Schwartz, Mary R.
    Mody, Dina R.
    Ge, Yimin
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2018, 142 (03) : 347 - 352
  • [32] Association of Human Papillomavirus Genotype 16 Viral Variant and Viral Load with Cervical High-grade Intraepithelial Lesions
    Alvarez-Paredes, Ledicia
    Santibanez, Miguel
    Galiana, Antonio
    Rodriguez Diaz, Juan Carlos
    Paras-Bravo, Paula
    Encarnacion Andrada-Becerra, Ma
    Ruiz Garcia, Maria Montserrat
    Maria Rodriguez-Ingelmo, Jose
    Portilla-Sogorb, Joaquin
    Paz-Zulueta, Maria
    CANCER PREVENTION RESEARCH, 2019, 12 (08) : 547 - 555
  • [33] Detection of human papillomavirus 67 single infection in high-grade cervical lesions: Case report and review of literature
    Steven, Van Schandevyl
    Liselotte, Coorevits
    Jerina, Boelens
    Ans, Traen
    Luc, Binge
    Marleen, Praet
    Jo, Van Dorpe
    Elizaveta, Padalko
    DIAGNOSTIC CYTOPATHOLOGY, 2019, 47 (03) : 251 - 254
  • [34] Human papillomavirus types in cervical high-grade lesions or cancer among Nordic women-Potential for prevention
    de la Cour, Cecilie Dovey
    Guleria, Sonia
    Nygard, Mari
    Trygvadottir, Laufey
    Sigurdsson, Kristjan
    Liaw, Kai-Li
    Hortlund, Maria
    Lagheden, Camilla
    Hansen, Bo T.
    Munk, Christian
    Dillner, Joakim
    Kjaer, Susanne K.
    CANCER MEDICINE, 2019, 8 (02): : 839 - 849
  • [35] The role of human papillomavirus testing after treatment for high-grade cervical dysplasia
    Turner, Taylor B.
    Huh, Warner K.
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2016, 27 (01)
  • [36] Trends in High-Grade Cervical Cancer Precursors in the Human Papillomavirus Vaccine Era
    Oakley, Fredrick
    Desouki, Mohamed M.
    Pemmaraju, Manideepthi
    Gargano, Julia M.
    Markowitz, Lauri E.
    Steinau, Martin
    Unger, Elizabeth R.
    Zhu, Yuwei
    Fadare, Oluwole
    Griffin, Marie R.
    AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2018, 55 (01) : 19 - 25
  • [37] HUMAN PAPILLOMAVIRUS INFECTION AFTER TREATMENT FOR HIGH-GRADE CERVICAL INTRAEPITHELIAL NEOPLASIA
    Shikova, E.
    Ivanova, Z.
    Zvirbliene, A.
    Ganchev, G.
    BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2012, 26 : 85 - 88
  • [38] Effectiveness of quadrivalent human papillomavirus vaccination against high-grade cervical lesions by age and doses: a population-based cohort study
    Wu, Shiqiang
    Ploner, Alexander
    Alsina, Ana Martina Astorga
    Deng, Yunyang
    Schollin, Lina Ask
    Lei, Jiayao
    LANCET REGIONAL HEALTH-EUROPE, 2025, 49
  • [39] Human papillomavirus type 52 polymorphism and high-grade lesions of the uterine cervix
    Formentin, Aurelie
    Archambault, Jacques
    Koushik, Anita
    Richardson, Harriet
    Brassard, Paul
    Franco, Eduardo L.
    Coutlee, Francois
    INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (08) : 1821 - 1830
  • [40] Molecular Signatures of High-Grade Cervical Lesions
    Porcari, Andreia M.
    Negrao, Fernanda
    Tripodi, Guilherme Lucas
    Pitta, Denise Rocha
    Campos, Elisabete Aparecida
    Montis, Douglas Munhoz
    Martins, Aline M. A.
    Eberlin, Marcos N.
    Derchain, Sophie F. M.
    FRONTIERS IN ONCOLOGY, 2018, 8